Crispr Therapeutics AG

Crispr Therapeutics AG is a biotechnology company specializing in the development of transformative gene-based medicines through CRISPR/Cas9 gene-editing technology. Headquartered in Zug, Switzerland, with research and manufacturing operations in the US and Europe, the company focuses on creating therapies aimed at curing serious diseases. Its therapeutic programs span several fields, including hemoglobinopathies (such as sickle cell disease and transfusion-dependent beta thalassemia), immuno-oncology, autoimmune disorders, and type 1 diabetes. Notably, Crispr Therapeutics AG, in collaboration with Vertex Pharmaceuticals, achieved a significant milestone with the regulatory approval of Casgevy, a groundbreaking gene-editing treatment for severe sickle cell disease and beta thalassemia. The company’s portfolio features both approved and investigative therapies that leverage precise genome editing to address the underlying genetic causes of disease. By pioneering the clinical application of CRISPR technology, the company plays a key role in advancing gene therapy and has established itself as a leader in the biopharmaceutical sector, recognized for its innovation and commitment to addressing unmet medical needs.